Emergent BioSolutions (EBS) said Tuesday that it has obtained exclusive commercial rights in the US and Canada to Hikma Pharmaceuticals' Kloxxado Nasal Spray, an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose.
Financial terms were not disclosed.
Under the terms of the six-year agreement, Emergent said Hikma will continue to manufacture Kloxxado Nasal Spray 8 mg, which will become part of Emergent's NARCANDirect online distribution network for direct purchasers, such as emergency medical services.
Emergent's shares were up about 3% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.